ID   NMT1_HUMAN              Reviewed;         496 AA.
AC   P30419; A8K7C1; Q9UE09;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 2.
DT   28-JUN-2023, entry version 217.
DE   RecName: Full=Glycylpeptide N-tetradecanoyltransferase 1 {ECO:0000305};
DE            EC=2.3.1.97 {ECO:0000269|PubMed:22865860, ECO:0000269|PubMed:25255805, ECO:0000269|PubMed:9353336, ECO:0000269|PubMed:9506952};
DE   AltName: Full=Myristoyl-CoA:protein N-myristoyltransferase 1;
DE            Short=HsNMT1 {ECO:0000303|PubMed:32111831};
DE            Short=NMT 1;
DE            Short=Type I N-myristoyltransferase;
DE   AltName: Full=Peptide N-myristoyltransferase 1;
DE   AltName: Full=Protein-lysine myristoyltransferase NMT1 {ECO:0000305};
DE            EC=2.3.1.- {ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831};
GN   Name=NMT1 {ECO:0000303|PubMed:9506952, ECO:0000312|HGNC:HGNC:7857};
GN   Synonyms=NMT {ECO:0000303|PubMed:9353336};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=9353336; DOI=10.1074/jbc.272.45.28680;
RA   Glover C.J., Hartman K.D., Felsted R.L.;
RT   "Human N-myristoyltransferase amino-terminal domain involved in targeting
RT   the enzyme to the ribosomal subcellular fraction.";
RL   J. Biol. Chem. 272:28680-28689(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Brain;
RX   PubMed=9506952; DOI=10.1074/jbc.273.12.6595;
RA   Giang D.K., Cravatt B.F.;
RT   "A second mammalian N-myristoyltransferase.";
RL   J. Biol. Chem. 273:6595-6598(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND SHORT).
RC   TISSUE=Muscle, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 58-496, TISSUE SPECIFICITY, AND MUTAGENESIS
RP   OF GLY-492.
RX   PubMed=1570339; DOI=10.1073/pnas.89.9.4129;
RA   Duronio R.J., Reed S.I., Gordon J.I.;
RT   "Mutations of human myristoyl-CoA:protein N-myristoyltransferase cause
RT   temperature-sensitive myristic acid auxotrophy in Saccharomyces
RT   cerevisiae.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4129-4133(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 81-89.
RX   PubMed=9677304; DOI=10.1042/bj3330491;
RA   Mcilhinney R.A.J., Young K., Egerton M., Camble R., White A., Soloviev M.;
RT   "Characterization of human and rat brain myristoyl-CoA:protein N-
RT   myristoyltransferase: evidence for an alternative splice variant of the
RT   enzyme.";
RL   Biochem. J. 333:491-495(1998).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein phosphorylation
RT   analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [13]
RP   CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=22865860; DOI=10.1074/jbc.m112.393231;
RA   Montgomery C., Pei Z., Watkins P.A., Miziorko H.M.;
RT   "Identification and characterization of an extramitochondrial human 3-
RT   Hydroxy-3-methylglutaryl-CoA lyase.";
RL   J. Biol. Chem. 287:33227-33236(2012).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47 AND SER-83, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-47, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.61 ANGSTROMS) OF 115-496 IN COMPLEX WITH
RP   TETRADECANOYL-COA.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of human type-I N-myristoyltransferase with bound
RT   myristoyl-CoA and inhibitor DDD90055.";
RL   Submitted (SEP-2009) to the PDB data bank.
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.64 ANGSTROMS) OF 109-496 IN COMPLEX WITH
RP   TETRADECANOYL-COA, CATALYTIC ACTIVITY, AND FUNCTION.
RX   PubMed=25255805; DOI=10.1038/ncomms5919;
RA   Thinon E., Serwa R.A., Broncel M., Brannigan J.A., Brassat U., Wright M.H.,
RA   Heal W.P., Wilkinson A.J., Mann D.J., Tate E.W.;
RT   "Global profiling of co- and post-translationally N-myristoylated proteomes
RT   in human cells.";
RL   Nat. Commun. 5:4919-4919(2014).
RN   [19] {ECO:0007744|PDB:6PAV}
RP   X-RAY CRYSTALLOGRAPHY (2.52 ANGSTROMS) OF 109-496 IN COMPLEX WITH
RP   TETRADECANOYL-COA, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=32103017; DOI=10.1038/s41467-020-14893-x;
RA   Kosciuk T., Price I.R., Zhang X., Zhu C., Johnson K.N., Zhang S.,
RA   Halaby S.L., Komaniecki G.P., Yang M., DeHart C.J., Thomas P.M.,
RA   Kelleher N.L., Fromme J.C., Lin H.;
RT   "NMT1 and NMT2 are lysine myristoyltransferases regulating the ARF6 GTPase
RT   cycle.";
RL   Nat. Commun. 11:1067-1067(2020).
RN   [20] {ECO:0007744|PDB:6EHJ, ECO:0007744|PDB:6QRM, ECO:0007744|PDB:6SJZ, ECO:0007744|PDB:6SK2, ECO:0007744|PDB:6SK3, ECO:0007744|PDB:6SK8, ECO:0007744|PDB:6SKJ}
RP   X-RAY CRYSTALLOGRAPHY (1.87 ANGSTROMS) OF 99-493 IN COMPLEX WITH
RP   TETRADECANOYL-COA, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, AND MUTAGENESIS OF TYR-180; VAL-181 AND TYR-192.
RX   PubMed=32111831; DOI=10.1038/s41467-020-14847-3;
RA   Dian C., Perez-Dorado I., Riviere F., Asensio T., Legrand P., Ritzefeld M.,
RA   Shen M., Cota E., Meinnel T., Tate E.W., Giglione C.;
RT   "High-resolution snapshots of human N-myristoyltransferase in action
RT   illuminate a mechanism promoting N-terminal Lys and Gly myristoylation.";
RL   Nat. Commun. 11:1132-1132(2020).
CC   -!- FUNCTION: Adds a myristoyl group to the N-terminal glycine residue of
CC       certain cellular and viral proteins (PubMed:22865860, PubMed:25255805,
CC       PubMed:9353336, PubMed:9506952). Also able to mediate N-terminal lysine
CC       myristoylation of proteins: catalyzes myristoylation of ARF6 on both
CC       'Gly-2' and 'Lys-3' (PubMed:32103017, PubMed:32111831). Lysine
CC       myristoylation is required to maintain ARF6 on membranes during the
CC       GTPase cycle (PubMed:32103017). {ECO:0000269|PubMed:22865860,
CC       ECO:0000269|PubMed:25255805, ECO:0000269|PubMed:32103017,
CC       ECO:0000269|PubMed:32111831, ECO:0000269|PubMed:9353336,
CC       ECO:0000269|PubMed:9506952}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N-terminal glycyl-[protein] + tetradecanoyl-CoA = CoA + H(+) +
CC         N-tetradecanoylglycyl-[protein]; Xref=Rhea:RHEA:15521, Rhea:RHEA-
CC         COMP:12666, Rhea:RHEA-COMP:12667, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57385, ChEBI:CHEBI:64723,
CC         ChEBI:CHEBI:133050; EC=2.3.1.97;
CC         Evidence={ECO:0000269|PubMed:22865860, ECO:0000269|PubMed:25255805,
CC         ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831,
CC         ECO:0000269|PubMed:9353336, ECO:0000269|PubMed:9506952};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=N-terminal glycyl-L-lysyl-[protein] + tetradecanoyl-CoA = CoA
CC         + H(+) + N-terminal glycyl-(N(6)-tetradecanoyl)-L-lysyl-[protein];
CC         Xref=Rhea:RHEA:70671, Rhea:RHEA-COMP:17947, Rhea:RHEA-COMP:17948,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:57287, ChEBI:CHEBI:57385,
CC         ChEBI:CHEBI:189855, ChEBI:CHEBI:189856;
CC         Evidence={ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:70672;
CC         Evidence={ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=18 uM for tetradecanoyl-CoA {ECO:0000269|PubMed:32111831};
CC         Note=kcat is 0.41 sec(-1) with tetradecanoyl-CoA as substrate.
CC         {ECO:0000269|PubMed:32111831};
CC   -!- INTERACTION:
CC       P30419; Q9BR61: ACBD6; NbExp=5; IntAct=EBI-5280164, EBI-2848793;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9353336,
CC       ECO:0000269|PubMed:9506952}. Cytoplasm, cytosol
CC       {ECO:0000269|PubMed:9353336}. Membrane {ECO:0000269|PubMed:9506952};
CC       Peripheral membrane protein {ECO:0000269|PubMed:9506952}.
CC       Note=Copurifies with ribosomes. {ECO:0000269|PubMed:9353336}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P30419-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P30419-2; Sequence=VSP_003570;
CC   -!- TISSUE SPECIFICITY: Heart, gut, kidney, liver and placenta.
CC       {ECO:0000269|PubMed:1570339}.
CC   -!- SIMILARITY: Belongs to the NMT family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC09294.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/43604/NMT1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF043324; AAC09294.1; ALT_INIT; mRNA.
DR   EMBL; AF020500; AAB95316.1; -; mRNA.
DR   EMBL; AK291936; BAF84625.1; -; mRNA.
DR   EMBL; CH471178; EAW51554.1; -; Genomic_DNA.
DR   EMBL; BC006538; AAH06538.1; -; mRNA.
DR   EMBL; BC006569; AAH06569.1; -; mRNA.
DR   EMBL; BC007258; AAH07258.2; -; mRNA.
DR   EMBL; BC008312; AAH08312.2; -; mRNA.
DR   EMBL; M86707; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; Y17208; CAA76685.1; -; mRNA.
DR   EMBL; Y17209; CAA76686.1; -; mRNA.
DR   CCDS; CCDS11494.1; -. [P30419-1]
DR   PIR; JC1343; JC1343.
DR   RefSeq; NP_066565.1; NM_021079.4. [P30419-1]
DR   PDB; 1RXT; X-ray; 3.00 A; A/B/C/D=1-496.
DR   PDB; 3IU1; X-ray; 1.42 A; A/B=115-496.
DR   PDB; 3IU2; X-ray; 1.73 A; A/B=115-496.
DR   PDB; 3IWE; X-ray; 1.79 A; A/B=115-496.
DR   PDB; 3JTK; X-ray; 1.61 A; A/B=115-496.
DR   PDB; 4C2Y; X-ray; 1.64 A; A/B=109-496.
DR   PDB; 4C2Z; X-ray; 2.08 A; A/B=109-496.
DR   PDB; 5MU6; X-ray; 1.88 A; A/B=109-496.
DR   PDB; 5NPQ; X-ray; 2.37 A; A/B=109-496.
DR   PDB; 5O6H; X-ray; 1.29 A; A/B=109-496.
DR   PDB; 5O6J; X-ray; 1.45 A; A/B=109-496.
DR   PDB; 5O9S; X-ray; 2.70 A; A/B=99-496.
DR   PDB; 5O9T; X-ray; 2.15 A; A/B=99-496.
DR   PDB; 5O9U; X-ray; 1.85 A; A/B=99-496.
DR   PDB; 5O9V; X-ray; 2.20 A; A/B=99-496.
DR   PDB; 5UUT; X-ray; 2.25 A; A/B=109-496.
DR   PDB; 6EHJ; X-ray; 2.10 A; A/B=109-496.
DR   PDB; 6F56; X-ray; 1.94 A; A/B/C/D=109-496.
DR   PDB; 6FZ2; X-ray; 2.05 A; A/B=115-496.
DR   PDB; 6FZ3; X-ray; 2.00 A; A/B=115-496.
DR   PDB; 6FZ5; X-ray; 1.89 A; A/B=115-496.
DR   PDB; 6PAV; X-ray; 2.52 A; A/B=109-496.
DR   PDB; 6QRM; X-ray; 2.30 A; A/B=99-496.
DR   PDB; 6SJZ; X-ray; 2.00 A; A/B=99-496.
DR   PDB; 6SK2; X-ray; 1.90 A; A/B=99-496.
DR   PDB; 6SK3; X-ray; 2.70 A; A/B=99-493.
DR   PDB; 6SK8; X-ray; 1.87 A; A/B=99-493.
DR   PDB; 6SKJ; X-ray; 2.80 A; A/B=99-494.
DR   PDB; 7OWM; X-ray; 1.50 A; A/B=99-496.
DR   PDB; 7OWN; X-ray; 2.10 A; A/B=99-496.
DR   PDB; 7OWO; X-ray; 1.70 A; A/B=99-496.
DR   PDB; 7OWP; X-ray; 1.81 A; A/B=99-496.
DR   PDB; 7OWQ; X-ray; 3.00 A; A/B=99-496.
DR   PDB; 7OWR; X-ray; 2.39 A; A/B=99-496.
DR   PDB; 7OWU; X-ray; 2.08 A; A/B=99-496.
DR   PDB; 7RK3; X-ray; 2.05 A; A=109-496.
DR   PDBsum; 1RXT; -.
DR   PDBsum; 3IU1; -.
DR   PDBsum; 3IU2; -.
DR   PDBsum; 3IWE; -.
DR   PDBsum; 3JTK; -.
DR   PDBsum; 4C2Y; -.
DR   PDBsum; 4C2Z; -.
DR   PDBsum; 5MU6; -.
DR   PDBsum; 5NPQ; -.
DR   PDBsum; 5O6H; -.
DR   PDBsum; 5O6J; -.
DR   PDBsum; 5O9S; -.
DR   PDBsum; 5O9T; -.
DR   PDBsum; 5O9U; -.
DR   PDBsum; 5O9V; -.
DR   PDBsum; 5UUT; -.
DR   PDBsum; 6EHJ; -.
DR   PDBsum; 6F56; -.
DR   PDBsum; 6FZ2; -.
DR   PDBsum; 6FZ3; -.
DR   PDBsum; 6FZ5; -.
DR   PDBsum; 6PAV; -.
DR   PDBsum; 6QRM; -.
DR   PDBsum; 6SJZ; -.
DR   PDBsum; 6SK2; -.
DR   PDBsum; 6SK3; -.
DR   PDBsum; 6SK8; -.
DR   PDBsum; 6SKJ; -.
DR   PDBsum; 7OWM; -.
DR   PDBsum; 7OWN; -.
DR   PDBsum; 7OWO; -.
DR   PDBsum; 7OWP; -.
DR   PDBsum; 7OWQ; -.
DR   PDBsum; 7OWR; -.
DR   PDBsum; 7OWU; -.
DR   PDBsum; 7RK3; -.
DR   AlphaFoldDB; P30419; -.
DR   SMR; P30419; -.
DR   BioGRID; 110899; 154.
DR   IntAct; P30419; 44.
DR   MINT; P30419; -.
DR   STRING; 9606.ENSP00000468424; -.
DR   BindingDB; P30419; -.
DR   ChEMBL; CHEMBL2593; -.
DR   DrugBank; DB03062; (1-Methyl-1h-Imidazol-2-Yl)-(3-Methyl-4-{3-[(Pyridin-3-Ylmethyl)-Amino]-Propoxy}-Benzofuran-2-Yl)-Methanone.
DR   SwissLipids; SLP:000001287; -.
DR   GlyGen; P30419; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P30419; -.
DR   MetOSite; P30419; -.
DR   PhosphoSitePlus; P30419; -.
DR   SwissPalm; P30419; -.
DR   BioMuta; NMT1; -.
DR   DMDM; 12231020; -.
DR   EPD; P30419; -.
DR   jPOST; P30419; -.
DR   MassIVE; P30419; -.
DR   MaxQB; P30419; -.
DR   PaxDb; P30419; -.
DR   PeptideAtlas; P30419; -.
DR   ProteomicsDB; 54667; -. [P30419-1]
DR   ProteomicsDB; 54668; -. [P30419-2]
DR   TopDownProteomics; P30419-2; -. [P30419-2]
DR   Antibodypedia; 17578; 216 antibodies from 25 providers.
DR   DNASU; 4836; -.
DR   Ensembl; ENST00000258960.7; ENSP00000258960.2; ENSG00000136448.13. [P30419-1]
DR   Ensembl; ENST00000592654.3; ENSP00000466827.2; ENSG00000136448.13. [P30419-2]
DR   Ensembl; ENST00000592782.5; ENSP00000468424.1; ENSG00000136448.13. [P30419-1]
DR   Ensembl; ENST00000676828.1; ENSP00000504192.1; ENSG00000136448.13. [P30419-1]
DR   Ensembl; ENST00000678938.1; ENSP00000503621.1; ENSG00000136448.13. [P30419-2]
DR   GeneID; 4836; -.
DR   KEGG; hsa:4836; -.
DR   MANE-Select; ENST00000258960.7; ENSP00000258960.2; NM_021079.5; NP_066565.1.
DR   UCSC; uc002ihz.4; human. [P30419-1]
DR   AGR; HGNC:7857; -.
DR   CTD; 4836; -.
DR   DisGeNET; 4836; -.
DR   GeneCards; NMT1; -.
DR   HGNC; HGNC:7857; NMT1.
DR   HPA; ENSG00000136448; Low tissue specificity.
DR   MIM; 160993; gene.
DR   neXtProt; NX_P30419; -.
DR   OpenTargets; ENSG00000136448; -.
DR   PharmGKB; PA31661; -.
DR   VEuPathDB; HostDB:ENSG00000136448; -.
DR   eggNOG; KOG2779; Eukaryota.
DR   GeneTree; ENSGT00390000017837; -.
DR   HOGENOM; CLU_022882_1_0_1; -.
DR   InParanoid; P30419; -.
DR   OMA; EHDVEHW; -.
DR   OrthoDB; 777at2759; -.
DR   PhylomeDB; P30419; -.
DR   BRENDA; 2.3.1.97; 2681.
DR   PathwayCommons; P30419; -.
DR   Reactome; R-HSA-162599; Late Phase of HIV Life Cycle.
DR   Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade.
DR   Reactome; R-HSA-75108; Activation, myristolyation of BID and translocation to mitochondria.
DR   SignaLink; P30419; -.
DR   SIGNOR; P30419; -.
DR   BioGRID-ORCS; 4836; 489 hits in 1171 CRISPR screens.
DR   ChiTaRS; NMT1; human.
DR   EvolutionaryTrace; P30419; -.
DR   GeneWiki; N-myristoyltransferase_1; -.
DR   GenomeRNAi; 4836; -.
DR   Pharos; P30419; Tchem.
DR   PRO; PR:P30419; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P30419; protein.
DR   Bgee; ENSG00000136448; Expressed in monocyte and 207 other tissues.
DR   ExpressionAtlas; P30419; baseline and differential.
DR   Genevisible; P30419; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005739; C:mitochondrion; IEA:GOC.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004379; F:glycylpeptide N-tetradecanoyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0019107; F:myristoyltransferase activity; IDA:BHF-UCL.
DR   GO; GO:0018030; F:peptidyl-lysine N6-myristoyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0042180; P:cellular ketone metabolic process; IDA:BHF-UCL.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0018008; P:N-terminal peptidyl-glycine N-myristoylation; IDA:UniProtKB.
DR   GO; GO:0006499; P:N-terminal protein myristoylation; TAS:Reactome.
DR   GO; GO:1900740; P:positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway; TAS:Reactome.
DR   GO; GO:0022400; P:regulation of rhodopsin mediated signaling pathway; TAS:Reactome.
DR   CDD; cd04301; NAT_SF; 1.
DR   Gene3D; 3.40.630.170; -; 1.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR000903; NMT.
DR   InterPro; IPR022677; NMT_C.
DR   InterPro; IPR022678; NMT_CS.
DR   InterPro; IPR022676; NMT_N.
DR   PANTHER; PTHR11377:SF7; GLYCYLPEPTIDE N-TETRADECANOYLTRANSFERASE 1; 1.
DR   PANTHER; PTHR11377; N-MYRISTOYL TRANSFERASE; 1.
DR   Pfam; PF01233; NMT; 1.
DR   Pfam; PF02799; NMT_C; 1.
DR   PIRSF; PIRSF015892; N-myristl_transf; 1.
DR   SUPFAM; SSF55729; Acyl-CoA N-acyltransferases (Nat); 2.
DR   PROSITE; PS00975; NMT_1; 1.
DR   PROSITE; PS00976; NMT_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acyltransferase; Alternative splicing; Cytoplasm; Membrane;
KW   Phosphoprotein; Reference proteome; Transferase.
FT   CHAIN           1..496
FT                   /note="Glycylpeptide N-tetradecanoyltransferase 1"
FT                   /id="PRO_0000064221"
FT   REGION          1..82
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         118
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32111831, ECO:0000269|Ref.17"
FT   BINDING         119
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831,
FT                   ECO:0000269|Ref.17"
FT   BINDING         120
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831,
FT                   ECO:0000269|Ref.17"
FT   BINDING         247
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:32103017"
FT   BINDING         248
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831,
FT                   ECO:0000269|Ref.17"
FT   BINDING         249
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805, ECO:0000269|Ref.17"
FT   BINDING         250
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831,
FT                   ECO:0000269|Ref.17"
FT   BINDING         256
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32103017, ECO:0000269|PubMed:32111831,
FT                   ECO:0000269|Ref.17"
FT   BINDING         258
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32111831, ECO:0000269|Ref.17"
FT   BINDING         259
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32111831, ECO:0000269|Ref.17"
FT   BINDING         260
FT                   /ligand="tetradecanoyl-CoA"
FT                   /ligand_id="ChEBI:CHEBI:57385"
FT                   /evidence="ECO:0000269|PubMed:25255805,
FT                   ECO:0000269|PubMed:32111831, ECO:0000269|Ref.17"
FT   MOD_RES         31
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O70310"
FT   MOD_RES         47
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:16964243,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         83
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..80
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_003570"
FT   VARIANT         61
FT                   /note="Q -> K (in dbSNP:rs3087878)"
FT                   /id="VAR_050286"
FT   MUTAGEN         180
FT                   /note="Y->P: Abolished glycine- and
FT                   lysine-myristoyltransferase activites."
FT                   /evidence="ECO:0000269|PubMed:32111831"
FT   MUTAGEN         181
FT                   /note="V->L: Reduced glycine N-myristoyltransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:32111831"
FT   MUTAGEN         192
FT                   /note="Y->A: Reduced glycine N-myristoyltransferase
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:32111831"
FT   MUTAGEN         492
FT                   /note="G->D,K: Reduced activity."
FT                   /evidence="ECO:0000269|PubMed:1570339"
FT   STRAND          106..108
FT                   /evidence="ECO:0007829|PDB:5O9V"
FT   HELIX           109..113
FT                   /evidence="ECO:0007829|PDB:5O9U"
FT   HELIX           120..122
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          123..125
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          128..130
FT                   /evidence="ECO:0007829|PDB:6SK2"
FT   STRAND          156..160
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           166..179
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          188..190
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           194..201
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           208..210
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          211..216
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   TURN            217..219
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          222..235
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          238..250
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           252..254
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           255..257
FT                   /evidence="ECO:0007829|PDB:5O9S"
FT   HELIX           260..272
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   TURN            273..275
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          279..285
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          291..302
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           303..308
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           320..327
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          338..340
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           343..345
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           346..357
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          360..365
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           368..375
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   TURN            379..381
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          382..388
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          390..392
FT                   /evidence="ECO:0007829|PDB:1RXT"
FT   STRAND          394..402
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          405..407
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          418..421
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          427..429
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           431..444
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          448..454
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           458..460
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   TURN            461..466
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   STRAND          468..480
FT                   /evidence="ECO:0007829|PDB:5O6H"
FT   HELIX           488..490
FT                   /evidence="ECO:0007829|PDB:5O6H"
SQ   SEQUENCE   496 AA;  56806 MW;  7661140D3837BE7A CRC64;
     MADESETAVK PPAPPLPQMM EGNGNGHEHC SDCENEEDNS YNRGGLSPAN DTGAKKKKKK
     QKKKKEKGSE TDSAQDQPVK MNSLPAERIQ EIQKAIELFS VGQGPAKTME EASKRSYQFW
     DTQPVPKLGE VVNTHGPVEP DKDNIRQEPY TLPQGFTWDA LDLGDRGVLK ELYTLLNENY
     VEDDDNMFRF DYSPEFLLWA LRPPGWLPQW HCGVRVVSSR KLVGFISAIP ANIHIYDTEK
     KMVEINFLCV HKKLRSKRVA PVLIREITRR VHLEGIFQAV YTAGVVLPKP VGTCRYWHRS
     LNPRKLIEVK FSHLSRNMTM QRTMKLYRLP ETPKTAGLRP METKDIPVVH QLLTRYLKQF
     HLTPVMSQEE VEHWFYPQEN IIDTFVVENA NGEVTDFLSF YTLPSTIMNH PTHKSLKAAY
     SFYNVHTQTP LLDLMSDALV LAKMKGFDVF NALDLMENKT FLEKLKFGIG DGNLQYYLYN
     WKCPSMGAEK VGLVLQ
//
